Evaluation of the effects of propylisopropylacetic acid (PIA) on neuronal growth cone morphology

Neuropharmacology

Volumn 56, Issue 4, 2009, Pages 831-837

  Shimshoni, Jakob A ^a   Dalton, Emma C ^b   Watson, Peter ^b   Yagen, Boris ^a   Bialer, Meir ^a   Harwood, Adrian J ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Actin cytoskeleton; Carbamazepine; Lithium; Neuronal growth cones; Propylisopropylacetic acid; Valproate

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; F ACTIN; INOSITOL; LITHIUM; MOOD STABILIZER; PROPYLISOPROPYLACETIC ACID; T CELL FACTOR PROTEIN; UNCLASSIFIED DRUG; VALPROIC ACID;

ACTIN FILAMENT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; ENANTIOMER; GENE EXPRESSION; GROWTH CONE; MORPHOLOGY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN POLYMERIZATION; RACEMIC MIXTURE; RAT; SPINAL GANGLION;

ACTINS; ANIMALS; ANIMALS, NEWBORN; ANTIMANIC AGENTS; CARBAMAZEPINE; CYTOSKELETON; GANGLIA, SPINAL; GENE EXPRESSION; GROWTH CONES; IMMUNOHISTOCHEMISTRY; LITHIUM CHLORIDE; NEURONS; ORGAN CULTURE TECHNIQUES; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; T-LYMPHOCYTES; VALPROIC ACID;

EID: 60149085100     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.01.014     Document Type: Article

References (41)

1. Adler C.M., Levine A.D., DelBello M.P., and Strakowski S.M. Changes in gray matter volume in patients with bipolar disorder. Biol. Psychiatr. 58 (2005) 151-157
2. Atack J.R., Broughton H.B., and Pollack S.J. Structure and mechanism of inositol monophosphatase. FEBS Lett. 361 (1995) 1-7
3. Beaulieu J.M., Sotnikova T.D., Yao W.D., Kockeritz L., Woodgett J.R., Gainetdinov R.R., and Caron M.G. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 5099-5104
4. Berridge M.J., Downes C.P., and Hanley M.R. Neural and developmental actions of lithium: a unifying hypothesis. Cell 59 (1989) 411-419
5. Bottenstein J., Hayashi I., Hutchings S., Masui H., Mather J., McClure D.B., Ohasa S., Rizzino A., Sato G., Serrero G., Wolfe R., and Wu R. The growth of cells in serum-free hormone-supplemented media. Methods Enzymol. 58 (1979) 94-109
6. Chen G., Huang L.D., Jiang Y.M., and Manji H.K. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J. Neurochem. 72 (1999) 1327-1330
7. Cryan J.F., and Slattery D.A. Animal models of mood disorders: recent developments. Curr. Opin. Psychiatr. 20 (2007) 1-7
8. Dent E.W., and Gertler F.B. Cytoskeletal dynamics and transport in growth cone motility and axon guidance. Neuron 40 (2003) 209-227
9. Eickholt B.J., Towers G.J., Ryves W.J., Eikel D., Adley K., Ylinen L.M., Chadborn N.H., Harwood A.J., Nau H., and Williams R.S. Effects of valproic acid derivatives on inositol trisphosphate depletion, teratogenicity, glycogen synthase kinase-3beta inhibition, and viral replication: a screening approach for new bipolar disorder drugs derived from the valproic acid core structure. Mol. Pharmacol. 67 (2005) 1426-1433
10. Eickholt B.J., Williams R.S.B., and Harwood A.J. Mood stabilizers and the cell biology of neuronal growth cones. Clin. Neurosci. Res. 4 (2004) 189-199
11. Frey B.N., Andreazza A.C., Nery F.G., Martins M.R., Quevedo J., Soares J.C., and Kapczinski F. The role of hippocampus in the pathophysiology of bipolar disorder. Behav. Pharmacol. 18 (2007) 419-430
12. Frey B.N., Fonseca M.M., Machado-Vieira R., Soares J.C., and Kapczinski F. Neuropathological and neurochemical abnormalities in bipolar disorder. Rev. Bras. Pisquiatr. 26 (2004) 180-188
13. Goold R.G., Owen R., and Gordon-Weeks P.R. Glycogen synthase kinase 3beta phosphorylation of microtubule-associated protein 1B regulates the stability of microtubules in growth cones. J. Cell Sci. 112 Pt 19 (1999) 3373-3384
14. Gould T.D., Dow E.R., O'Donnell K.C., Chen G., and Manji H.K. Targeting signal transduction pathways in the treatment of mood disorders: recent insights into the relevance of the Wnt pathway. CNS Neurol. Disord. Drug Targets 6 (2007) 193-204
15. Gould T.D., Einat H., Bhat R., and Manji H.K. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int. J. Neuropsychopharmacol. 7 (2004) 387-390
16. Hall A.C., Brennan A., Goold R.G., Cleverley K., Lucas F.R., Gordon-Weeks P.R., and Salinas P.C. Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons. Mol. Cell. Neurosci. 20 (2002) 257-270
17. Hallcher L.M., and Sherman W.R. The effects of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. J. Biol. Chem. 255 (1980) 10896-10901
18. Harwood A.J., and Agam G. Search for a common mechanism of mood stabilizers. Biochem. Pharmacol. 66 (2003) 179-189
19. Kaidanovich-Beilin O., Milman A., Weizman A., Pick C.G., and Eldar-Finkelman H. Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol. Psychiatr. 55 (2004) 781-784
20. Klein P.S., and Melton D.A. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 8455-8459
21. Korinek V., Barker N., Morin P.J., van Wichen D., de Weger R., Kinzler K.W., Vogelstein B., and Clevers H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 275 (1997) 1784-1787
22. Lovestone S., Davis D.R., Webster M.T., Kaech S., Brion J.P., Matus A., and Anderton B.H. Lithium reduces tau phosphorylation: effects in living cells and in neurons at therapeutic concentrations. Biol. Psychiatr. 45 (1999) 995-1003
23. Lovestone S., Killick R., Di Forti M., and Murray R. Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci. 30 (2007) 142-149
24. Lucas F.R., Goold R.G., Gordon-Weeks P.R., and Salinas P.C. Inhibition of GSK-3beta leading to the loss of phosphorylated MAP-1B is an early event in axonal remodelling induced by WNT-7a or lithium. J. Cell Sci. 111 Pt 10 (1998) 1351-1361
25. Luo L. Actin cytoskeleton regulation in neuronal morphogenesis and structural plasticity. Annu. Rev. Cell Dev. Biol. 18 (2002) 601-635
26. Machado-Vieira R., Kapczinski F., and Soares J.C. Perspectives for the development of animal models of bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatr. 28 (2004) 209-224
27. +-induced inhibition of phosphoinositide turnover and ornithine decarboxylase induction during early lymphocyte activation. Eur. J. Immunol. 16 (1986) 859-861
28. O'Brien W.T., Harper A.D., Jove F., Woodgett J.R., Maretto S., Piccolo S., and Klein P.S. Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J. Neurosci. 24 (2004) 6791-6798
29. Owen R., and Gordon-Weeks P.R. Inhibition of glycogen synthase kinase 3beta in sensory neurons in culture alters filopodia dynamics and microtubule distribution in growth cones. Mol. Cell. Neurosci. 23 (2003) 626-637
30. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., and Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276 (2001) 36734-36741
31. Ryves W.J., Dalton E.C., Harwood A.J., and Williams R.S. GSK-3 activity in neocortical cells is inhibited by lithium but not carbamazepine or valproic acid. Bipolar Disord. 7 (2005) 260-265
32. Ryves W.J., and Harwood A.J. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem. Biophys. Res. Commun. 280 (2001) 720-725
33. Sang H., Lu Z., Li Y., Ru B., Wang W., and Chen J. Phosphorylation of tau by glycogen synthase kinase 3beta in intact mammalian cells influences the stability of microtubules. Neurosci. Lett. 312 (2001) 141-144
34. Shaltiel G., Shamir A., Shapiro J., Ding D., Dalton E., Bialer M., Harwood A.J., Belmaker R.H., Greenberg M.L., and Agam G. Valproate decreases inositol biosynthesis. Biol. Psychiatr. 56 (2004) 868-874
35. Shimshoni J.A., Dalton E.C., Jenkins A., Eyal S., Ewan K., Williams R.S., Pessah N., Yagen B., Harwood A.J., and Bialer M. The effects of central nervous system-active valproic acid constitutional isomers, cyclopropyl analogs, and amide derivatives on neuronal growth cone behavior. Mol. Pharmacol. 71 (2007) 884-892
36. Shimshoni J.A., Bialer M., Wlodarczyk B., Finnell R.H., and Yagen B. Potent anticonvulsant urea derivatives of constitutional isomers of valproic acid. J. Med. Chem. 50 (2007) 6419-6427
37. Silverstone P.H., Wu R.H., O'Donnell T., Ulrich M., Asghar S.J., and Hanstock C.C. Chronic treatment with both lithium and sodium valproate may normalize phosphoinositol cycle activity in bipolar patients. Hum. Psychopharmacol. 17 (2002) 321-327
38. Toledo E.M., Colombres M., and Inestrosa N.C. Wnt signaling in neuroprotection and stem cell differentiation. Prog. Neurobiol. 86 3 (2008) 281-296
39. Waites C.L., Craig A.M., and Garner C.C. Mechanisms of vertebrate synaptogenesis. Annu. Rev. Neurosci. 28 (2005) 251-274
40. Williams R., Ryves W.J., Dalton E.C., Eickholt B., Shaltiel G., Agam G., and Harwood A.J. A molecular cell biology of lithium. Biochem. Soc. Trans. 32 (2004) 799-802
41. Williams R.S., Cheng L., Mudge A.W., and Harwood A.J. A common mechanism of action for three mood-stabilizing drugs. Nature 417 (2002) 292-295